25.36

1.17% -0.30

Damora Therapeutics Inc (DMRA)

Overview News Price History Discussions Forecast

Damora Therapeutics Inc stock is traded at $25.36, with a volume of 226.89K. It is down -1.17% in the last 24 hours and up +1.12% over the past month. Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Previous Close:

$25.66

Open:

$25.5

24h Volume:

226.89K

Relative Volume:

1.51

Market Cap:

$1.53B

Revenue:

Net Income/Loss:

$-209.84M

P/E Ratio:

-5.5492

EPS:

-4.57

Net Cash Flow:

$-6.73M

1W Performance:

+2.46%

1M Performance:

+1.12%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$25.26

$26.29

1-Week Range:

$22.90

$26.29

52-Week Range:

$16.50

$28.76

Damora Therapeutics Inc Stock (DMRA) Company Profile

Name

Damora Therapeutics Inc

Sector

Healthcare (1113)

Industry

Biotechnology (622)

Phone

(781) 281-9020

Address

221 CRESCENT STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

DMRA's Discussions on Twitter

Compare DMRA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DMRA Damora Therapeutics Inc	25.36	1.53B	0	-209.84M	-6.73M	-4.57
VRTX Vertex Pharmaceuticals Inc	423.92	107.83B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	701.42	73.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	783.50	48.72B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.11	39.51B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.86	32.66B	5.36B	287.73M	924.18M	2.5229

Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Initiated	RBC Capital Mkts	Outperform
Mar-25-26	Initiated	Evercore ISI	Outperform
Feb-17-26	Initiated	UBS	Buy
Jan-07-26	Initiated	Leerink Partners	Outperform
Dec-01-25	Initiated	Guggenheim	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Nov-23-20	Initiated	BofA Securities	Buy
Nov-23-20	Initiated	Credit Suisse	Outperform
Nov-23-20	Initiated	SVB Leerink	Outperform

View All

Damora Therapeutics Inc Stock (DMRA) Latest News

May 01, 2026

Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat

May 01, 2026

Two new Damora hires get stock options for 57,500 shares - Stock Titan

May 01, 2026

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 01, 2026

Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat

May 01, 2026

Apr 30, 2026

Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat

Apr 30, 2026

Apr 29, 2026

Damora Therapeutics (NASDAQ: DMRA) sets 2026 virtual meeting, director votes and say-on-pay - Stock Titan

Apr 29, 2026

Apr 28, 2026

Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat

Apr 28, 2026

Apr 25, 2026

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Upgraded at Royal Bank Of Canada - MarketBeat

Apr 25, 2026

Apr 24, 2026

DMRA Initiated Coverage by RBC Capital -- Price Target Set at $4 - GuruFocus

Apr 24, 2026

Royal Bank Of Canada Begins Coverage on Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) - MarketBeat

Apr 24, 2026

RBC Initiates Damora Therapeutics at Outperform, Speculative Risk With $40 Price Target - marketscreener.com

Apr 24, 2026

Apr 23, 2026

Paramora Holding LLC owns 2,045,473 shares — Damora (NASDAQ: DMRA) - Stock Titan

Apr 23, 2026

RBC initiates Damora Therapeutics stock at Outperform, $40 target By Investing.com - Investing.com South Africa

Apr 23, 2026

RBC initiates Damora Therapeutics stock at Outperform, $40 target - Investing.com UK

Apr 23, 2026